These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24432510)

  • 21. Posttransplant lymphoproliferative disorder with lung involvement in a renal transplant recipient.
    Mirza EI; Mutluay R; Suyani E; Okyay GU; Akyurek N; Aki SZ; Derici U; Arinsoy T
    Exp Clin Transplant; 2011 Dec; 9(6):425-8. PubMed ID: 22142053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-intensity chemotherapy and rituximab for the treatment of posttransplant lymphoproliferative disorder.
    Chen RW; Sweetenham JW
    Am J Clin Oncol; 2006 Apr; 29(2):211-2. PubMed ID: 16601446
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
    Morgan SJ; Seymour JF; Grigg A; Matthews JP; Prince HM; Wolf MM; Januszewicz EH
    Leukemia; 2004 May; 18(5):1034-8. PubMed ID: 14990978
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders.
    Boratyńska M; Smolska D
    Transpl Int; 2008 Jun; 21(6):605-8. PubMed ID: 18282244
    [No Abstract]   [Full Text] [Related]  

  • 26. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene.
    Wei A; Cowie T
    Eur J Haematol; 2007 Oct; 79(4):363-6. PubMed ID: 17725802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies for posttransplant lymphoproliferative disorder.
    Perkins JD
    Liver Transpl; 2006 Jun; 12(6):1013-4. PubMed ID: 16823952
    [No Abstract]   [Full Text] [Related]  

  • 28. [Infectious complications as a consequence of treatment with nucleoside analogs and monoclonal antibodies].
    Maschmeyer G; Haas A
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2414-9. PubMed ID: 17054059
    [No Abstract]   [Full Text] [Related]  

  • 29. [Relation of beta 2 microglobulin and favorable therapeutic responses in malignant lymphoproliferative diseases].
    Opat P; Drbal J; Vyzula R; Wotke R; Tauer Z
    Vnitr Lek; 1988 Oct; 34(10):1010-2. PubMed ID: 3062884
    [No Abstract]   [Full Text] [Related]  

  • 30. Post-transplant lymphoproliferative disorders.
    Chetty R; Dada MA
    S Afr J Surg; 1998 Feb; 36(1):4, 6, 8-9. PubMed ID: 9601824
    [No Abstract]   [Full Text] [Related]  

  • 31. CD30+ lymphoproliferative disorders of the skin: still an open question.
    Alaibac M; Zarian H; Russo I; Peserico A
    G Ital Dermatol Venereol; 2012 Dec; 147(6):545-52. PubMed ID: 23149700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen for lymphangioleiomyomatosis.
    Tomasian A; Greenberg MS; Rumerman H
    N Engl J Med; 1982 Mar; 306(12):745-6. PubMed ID: 7062945
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunophenotyping of lymphoproliferative disorders: state of the art.
    Gudgin EJ; Erber WN
    Pathology; 2005 Dec; 37(6):457-78. PubMed ID: 16373227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Multidrug resistance in lymphoproliferative syndromes].
    Damiani D; Michelutti A; Michieli M; Geromin A; Raspadori D; Giacca M; Mallardi F; Baccarani M
    Haematologica; 1991 Jun; 76 Suppl 3():162-4. PubMed ID: 1684341
    [No Abstract]   [Full Text] [Related]  

  • 35. [The use of betamethasone in polychemotherapy of lymphoproliferative diseases].
    Cellerino R; Ambrosetti A; Tummarello D; Perini A; Piga A; Celebrano M
    Minerva Med; 1980 Sep; 71(32):2293-7. PubMed ID: 6933321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EBV-related lymphoproliferative disorders in immunocompetent patients.
    Oosterveld M; Lesterhuis WJ; MacKenzie M; van Krieken JH
    Leukemia; 2003 Dec; 17(12):2537-8. PubMed ID: 14523463
    [No Abstract]   [Full Text] [Related]  

  • 37. [Lymphoproliferative disorders].
    Nihon Rinsho; 1990 Jul; 48 Suppl():1064-211. PubMed ID: 2214197
    [No Abstract]   [Full Text] [Related]  

  • 38. [The characteristics of the clinical course and treatment of chronic obstructive lung diseases against a background of lymphoproliferative diseases].
    Provotorov VM; Kazabtsov AIu
    Ter Arkh; 1997; 69(3):19-23. PubMed ID: 9229820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A new effective therapy of hairy cell leukemia and other lymphoproliferative diseases].
    Juliusson G; Liliemark J
    Lakartidningen; 1991 Aug; 88(35):2746-9. PubMed ID: 1680209
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immunodiagnosis of lymphoproliferative diseases].
    Hokland P; Ellegaard J
    Ugeskr Laeger; 1981 Apr; 143(15):915-8. PubMed ID: 7025407
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.